Small molecule heparanase inhibitors as anti-metastatic cancer drugs
The Heparanib Proof-of-Concept project aims to establish the feasibility of our unique small molecule heparanase inhibitors as drug candidates for the treatment of metastatic cancers. To strengthen our science case (experimental d...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto HEPARANIB
Duración del proyecto: 17 meses
Fecha Inicio: 2023-06-01
Fecha Fin: 2024-11-30
Líder del proyecto
UNIVERSITEIT LEIDEN
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The Heparanib Proof-of-Concept project aims to establish the feasibility of our unique small molecule heparanase inhibitors as drug candidates for the treatment of metastatic cancers. To strengthen our science case (experimental development A) and by building on our in vivo data in mouse models for metastatic breast cancer, lung cancer and multiple myeloma, we will (A-I) design a suitable route of synthesis to prepare sufficient quantities of clinical grade material; (A-II) synthesise reference compounds; and (A-III) perform initial pharmacokinetics/pharmacodynamics (PK/PD) studies. With the aim to prepare for the establishment of a spin-out biotech company (business development B) to take our leads towards the clinic we will (B-IV) strengthen our intellectual property (IP) position; (B-V) perform an extensive analysis of the anti-metastatic cancer drug market; and (B-VI) prepare for commercialisation by consolidating the results in an investor-ready business plan to develop and commercialise our anticancer drug candidate.